Local and systemic thrombotic complications in cirrhotic patients with hepatocellular carcinoma

Abstract

Venous thromboembolic events (VTE) represent a significant and common complication in patients with hepatocellular carcinoma (HCC) in the context of cirrhosis. While some patient-related risk factors for VTE are shared with the non-cirrhotic population, the presence of HCC amplifies the risk, potentially due to the pro-thrombotic paraneoplastic alterations associated with the tumor. This review aims to examine the current evidence regarding hemostatic disorders observed specifically in cirrhotic patients with HCC. Additionally, the review comprehensively examines VTE events in cirrhotic patients with HCC, specifically emphasizing portal vein thrombosis (PVT). PVT is the most common thrombotic complication in this population and can have significant implications for the eligibility and success of treatment modalities such as liver transplants or surgical interventions. Identifying risk factors associated with PVT occurrence in these patients is essential to guide preventive measures and enhance patient outcomes. This review aims to provide a clear background for further research and investigations into effective prevention and treatment strategies for VTE in cirrhotic patients with HCC by comprehensively revising the current evidence on these topics.

Keywords

Hepatocellular carcinoma / portal vein thrombosis / anticoagulation / cirrhosis / deep vein thrombosis / venous thromboembolism

References

[1] Serrano PE,Linkins LA.Venous thromboembolic events following major pelvic and abdominal surgeries for cancer: a prospective cohort study.Ann Surg Oncol2018;25:3214-21

[2] Abdulla A,Ratnaweera N,Ballantyne Scott B.A meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer.Thromb Haemost2020;120:702-13

[3] Moik F,Wiedemann S.Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.Blood2021;137:1669-78 PMCID:PMC8016631

[4] Chew HK,Harvey D,White RH.Incidence of venous thromboembolism and its effect on survival among patients with common cancers.Arch Intern Med2006;166:458-64

[5] Khorana AA,Falanga A.Cancer-associated venous thromboembolism.Nat Rev Dis Primers2022;8:11

[6] Key NS,Kuderer NM.Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update.J Clin Oncol2020;38:496-520

[7] Falanga A,Vignoli A.Coagulation and cancer: biological and clinical aspects.J Thromb Haemost2013;11:223-33

[8] Dickmann B,Ay C.Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study.Haematologica2013;98:1309-14 PMCID:PMC3729913

[9] Blom JW,Rosendaal FR.The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma.J Thromb Haemost2004;2:1760-5

[10] Falanga A,Russo L.Procoagulant mechanisms in tumour cells.Best Pract Res Clin Haematol2009;22:49-60

[11] Ay C,Cohen AT.Cancer-associated venous thromboembolism: burden, mechanisms, and management.Thromb Haemost2017;117:219-30

[12] Khorana AA,Blumberg N,Refaai MA.Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer.Arch Intern Med2008;168:2377-81 PMCID:PMC2775132

[13] Ramsey G.Thrombosis risk in cancer patients receiving red blood cell transfusions.Semin Thromb Hemost2019;45:648-56

[14] Branchford BR.The role of inflammation in venous thromboembolism.Front Pediatr2018;6:142 PMCID:PMC5974100

[15] Willobee BA,Allen CJ.Minimally invasive surgery is associated with an increased risk of postoperative venous thromboembolism after distal pancreatectomy.Ann Surg Oncol2020;27:2498-505

[16] Connell NT,Brignardello-Petersen R.ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease.Blood Adv2021;5:301-25 PMCID:PMC7805326

[17] Lisman T,Intagliata NM.Haemostatic alterations and management of haemostasis in patients with cirrhosis.J Hepatol2022;76:1291-305

[18] Zanetto A,Pelizzaro F.Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications.Liver Int2022;42:1229-40

[19] Cohen AT,Rietbrock S,Martinez C.Epidemiology of first and recurrent venous thromboembolism in patients with active cancer: a population-based cohort study.Thromb Haemost2017;117:57-65

[20] Zanetto A,Vitale A.Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma.Dig Liver Dis2017;49:440-5

[21] Kinoshita A,Imai N.Elevated plasma fibrinogen levels are associated with a poor prognosis in patients with hepatocellular carcinoma.Oncology2013;85:269-77

[22] Thorson CM,Ryan ML.Pre-existing hypercoagulability in patients undergoing potentially curative cancer resection.Surgery2014;155:134-44

[23] Simpson-haidaris P.Tumors and fibrinogen: the role of fibrinogen as an extracellular matrix protein.Ann N Y Acad Sci2001;936:406-25

[24] Zanetto A,Bulato C.More pronounced hypercoagulable state and hypofibrinolysis in patients with cirrhosis with versus without HCC.Hepatol Commun2021;5:1987-2000

[25] Campello E,Spiezia L.Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis.Thromb Res2016;143:118-21

[26] Carr BI,Giannini EG.Italian Liver Cancer GroupSignificance of platelet and AFP levels and liver function parameters for HCC size and survival.Int J Biol Markers2014;29:e215-23

[27] Wang B,Ma X.Platelet activation status in the diagnosis and postoperative prognosis of hepatocellular carcinoma.Clin Chim Acta2019;495:191-7

[28] Liu PH,Su CW.Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma.Liver Int2020;40:2522-34 PMCID:PMC9023184

[29] Carr BI.Thrombocytosis and hepatocellular carcinoma.Dig Dis Sci2013;58:1790-6 PMCID:PMC3665764

[30] Scheiner B,Popp S.Association of platelet count and mean platelet volume with overall survival in patients with cirrhosis and unresectable hepatocellular carcinoma.Liver Cancer2019;8:203-17 PMCID:PMC6547277

[31] Hagiwara S,Kawasaki T.Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma.J Gastroenterol2006;41:1214-9

[32] Gade IL,Naess IA.The impact of initial cancer stage on the incidence of venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) Cohort.J Thromb Haemost2017;15:1567-75

[33] Hwang SJ,Li CP.Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma.World J Gastroenterol2004;10:2472-7 PMCID:PMC4572144

[34] Zanetto A,Campello E.Influence of hepatocellular carcinoma on platelet aggregation in cirrhosis.Cancers2021;13:1150 PMCID:PMC7962527

[35] Trebicka J,Papp M.PREDICT STUDY group of the EASL-CLIF ConsortiumThe PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology.J Hepatol2020;73:842-54

[36] Lesmana CR,Cahyadinata L.Deep vein thrombosis in patients with advanced liver cirrhosis: a rare condition?.Hepatol Int2010;4:433-8 PMCID:PMC2836440

[37] Yassine A, Abureesh M, Hamadi R, Dahabra L, Alshami M, Liliane D. Predictors of deep venous thrombosis in hospitalized patients with liver cirrhosis in the US.Cureus2022;14:e23450 PMCID:PMC9038512

[38] Faccia M,Gasbarrini A,Zocco MA.Risk factors for portal vein thrombosis or venous thromboembolism in a large cohort of hospitalized cirrhotic patients.Intern Emerg Med2022;17:1327-34 PMCID:PMC9352602

[39] Connolly GC,Hyrien O.Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma.Thromb Res2008;122:299-306 PMCID:PMC2496959

[40] Wang Y,Fuentes HE,Zhang H.Performance of Khorana risk score for prediction of venous thromboembolism in patients with hepatocellular carcinoma.Clin Appl Thromb Hemost2018;24:471-6 PMCID:PMC6714645

[41] Al-Taee AM,Khneizer GW.Correlates, trends, and short-term outcomes of venous thromboembolism in hospitalized patients with hepatocellular carcinoma.J Gastrointest Cancer2019;50:357-60

[42] Chen Y,Zhang Z.Construction and validation of a nomogram for predicting the risk of deep vein thrombosis in hepatocellular carcinoma patients after laparoscopic hepatectomy: a retrospective study.J Hepatocell Carcinoma2021;8:783-94 PMCID:PMC8312330

[43] Association for the Study of the Liver. Electronic address: [e-mail]. EASL clinical practice guidelines: vascular diseases of the liver.J Hepatol2016;64:179-202

[44] Senzolo M,Grasso M.Role of nonneoplastic PVT in the natural history of patients with cirrhosis and first diagnosis of HCC.Hepatology2024;79:355-67

[45] Sherman CB,Dodge JL,Yao FY.Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the A-VENA Criteria.Liver Transpl2019;25:207-16 PMCID:PMC7103424

[46] Llovet JM,Castells A.Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.Hepatology1999;29:62-7

[47] Minagawa M,Takayama T.Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus.Ann Surg2001;233:379-84 PMCID:PMC1421254

[48] Nonami T,Iwatsuki S.The incidence of portal vein thrombosis at liver transplantation.Hepatology1992;16:1195-8 PMCID:PMC2989675

[49] Davidson BR,Dick R,Rolles K.Incidence, risk factors, management, and outcome of portal vein abnormalities at orthotopic liver transplantation.Transplantation1994;57:1174-7

[50] Ravaioli M,Grazi GL.Portal vein thrombosis and liver transplantation: evolution during 10 years of experience at the University of Bologna.Ann Surg2011;253:378-84

[51] Cagin YF,Erdogan MA,Colak C.Incidence and clinical presentation of portal vein thrombosis in cirrhotic patients.Hepatobiliary Pancreat Dis Int2016;15:499-503

[52] Serag WM,Mohamed MM.Predicting the risk of portal vein thrombosis in patients with liver cirrhosis and hepatocellular carcinoma.Heliyon2020;6:e04677 PMCID:PMC7452450

[53] O'Shea RS,Ko CW.AGA clinical practice guideline on the management of coagulation disorders in patients with cirrhosis.Gastroenterology2021;161:1615-1627.e1

[54] Association for the Study of the Liver. Electronic address: [e-mail], European Association for the Study of the Liver. EASL clinical practice guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis.J Hepatol2022;76:1151-84

[55] Valeriani E,Riva N.Anticoagulant treatment for splanchnic vein thrombosis in liver cirrhosis: a systematic review and meta-analysis.Thromb Haemost2021;121:867-76

[56] Candeloro M,Monreal M.Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis.Blood Adv2022;6:4516-23 PMCID:PMC9636325

[57] Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C; Baveno VII Faculty. Baveno VII - renewing consensus in portal hypertension.J Hepatol2022;76:959-74

[58] Northup PG,Garcia-Tsao G.Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases.Hepatology2021;73:366-413